🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseNon-invasive MASH biomarkers — March 2026 Page 4

Non-invasive MASH biomarkers — March 2026

AttorneyGrant Mon, Nov 13, 2023 at 1:03 AM 54 replies 3,138 viewsPage 4 of 11
PeptideSynthNJ
Member
234
1,234
Aug 2024
Princeton, NJ
Nov 13, 2023 at 6:43 AM#16

Just wanted to say — for anyone reading this Non-invasive MASH thread who is feeling discouraged: it gets better. The first few weeks are the hardest. Hang in there. 💪

22 17wanda_boise, NurseAsh_DET, BenResearch_OR and 19 others
Reply Quote Save Share Report
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Nov 13, 2023 at 7:00 AM#17

AttorneyGrant's experience with Non-invasive MASH resonates deeply with mine. I went through almost the identical process — starting dose, titration timeline, side effects, everything.

The main difference: I titrated faster. But the overall trajectory has been remarkably similar. Down 48 lbs in 13 months.

One thing I would add that AttorneyGrant did not mention: the relationship with food fundamentally changed.

39 2PharmD_Rodriguez, julia.endo, JessicaM_2024 and 36 others
Reply Quote Save Share Report
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
Nov 13, 2023 at 7:17 AM#18

Saving this for reference. Quality thread.

50 11amsterdam_pete, LondonLisa, mike_nyc and 47 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Nov 13, 2023 at 7:34 AM#19

As a healthcare provider, I want to add some clinical context to this discussion on Non-invasive MASH biomarkers March 2026.

Building on what AttorneyGrant said — the evidence base here is well-established. The key publications to reference are from the STEP program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
8 7Dr.PeteFamMed, claudia_zurich, nancy_portland and 5 others
Reply Quote Save Share Report
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
Nov 13, 2023 at 7:51 AM#20

Subscribing to this thread. Non-invasive MASH is exactly what I've been researching. 🙏

26 1sarah.morrison, NeuroNate, JessicaH_TX and 23 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register